全文获取类型
收费全文 | 9095篇 |
免费 | 559篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 210篇 |
妇产科学 | 112篇 |
基础医学 | 1282篇 |
口腔科学 | 30篇 |
临床医学 | 860篇 |
内科学 | 2336篇 |
皮肤病学 | 118篇 |
神经病学 | 754篇 |
特种医学 | 353篇 |
外科学 | 1652篇 |
综合类 | 24篇 |
一般理论 | 2篇 |
预防医学 | 374篇 |
眼科学 | 75篇 |
药学 | 585篇 |
中国医学 | 22篇 |
肿瘤学 | 854篇 |
出版年
2023年 | 52篇 |
2022年 | 92篇 |
2021年 | 230篇 |
2020年 | 122篇 |
2019年 | 243篇 |
2018年 | 244篇 |
2017年 | 194篇 |
2016年 | 201篇 |
2015年 | 266篇 |
2014年 | 329篇 |
2013年 | 424篇 |
2012年 | 706篇 |
2011年 | 728篇 |
2010年 | 413篇 |
2009年 | 389篇 |
2008年 | 592篇 |
2007年 | 623篇 |
2006年 | 590篇 |
2005年 | 663篇 |
2004年 | 564篇 |
2003年 | 539篇 |
2002年 | 556篇 |
2001年 | 73篇 |
2000年 | 53篇 |
1999年 | 91篇 |
1998年 | 120篇 |
1997年 | 73篇 |
1996年 | 69篇 |
1995年 | 46篇 |
1994年 | 60篇 |
1993年 | 52篇 |
1992年 | 21篇 |
1991年 | 25篇 |
1990年 | 31篇 |
1989年 | 17篇 |
1988年 | 20篇 |
1987年 | 20篇 |
1986年 | 13篇 |
1985年 | 13篇 |
1984年 | 14篇 |
1983年 | 13篇 |
1982年 | 12篇 |
1981年 | 16篇 |
1980年 | 11篇 |
1979年 | 12篇 |
1976年 | 9篇 |
1975年 | 6篇 |
1973年 | 7篇 |
1972年 | 7篇 |
1971年 | 5篇 |
排序方式: 共有9698条查询结果,搜索用时 15 毫秒
1.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
2.
Thierry Patrice David Olivier Ludovic Bourre 《Journal of environmental pathology, toxicology and oncology》2006,25(1-2):467-485
Photodynamic therapy (PDT) is based on the selective light activation of an exogenously given drug to patients. PDT acts mainly on cell membranes either of neovascular endothelial cells or of cancer cells leading to cancer cell death. Six drugs are now marketed based on clinical assays in various indications, which showed a clear cost efficiency as compared to other classical procedures. PDT is easy to handle and can be performed in medical installations fitting the conditions of health care in developing countries. Its cost effectiveness could represent an appropriate solution to the increasing number of cancers of various origin. However despite all the clinical results now available, PDT development remains slow. The reasons for this situation include cost of development, intellectual property, and competition between pharmaceutical companies. 相似文献
3.
Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. 总被引:6,自引:0,他引:6
Thierry Buclin Monica Cosma Rochat Peter Burckhardt Mo?se Azria Martine Attinger 《Journal of bone and mineral research》2002,17(8):1478-1485
Salmon calcitonin (SCT) is a well-tolerated peptide drug with a wide therapeutic margin and is administered parenterally for long-term treatments of bone diseases. Its clinical usefulness would be enhanced by the development of an orally active formulation. In this randomized crossover double-blinded phase I trial, controlled by both a placebo and a parenteral verum, we have tested a new oral formulation of SCT associated with a caprylic acid derivative as carrier. Eight healthy volunteers received single doses of 400, 800, and 1200 microg of SCT orally, a placebo, and a 10-microg (50 IU) SCT intravenous infusion. SCT was reliably absorbed from the oral formulation, with an absolute bioavailability of 0.5-1.4%, depending on the dose. It induced a marked, dose-dependent drop in blood and urine C-terminal telopeptide of type I collagen (CTX), a sensitive and specific bone resorption marker, with the effects of 1200 microg exceeding those of 10 microg intravenously. It also decreased blood calcium and phosphate, and increased the circulating levels of parathyroid hormone (PTH) and, transiently, the urinary excretion of calcium. It was well-tolerated, with some subjects presenting mild and transient nausea, abdominal cramps, diarrheic stools, and headaches. This study shows that oral delivery of SCT is feasible with reproducible absorption and systemic biological efficacy. Such an oral formulation could facilitate the use of SCT in the treatment of osteoporosis and other bone diseases. 相似文献
4.
Y. Le Meur M. Büchler A. Thierry S. Caillard F. Villemain S. Lavaud I. Etienne P.-F. Westeel B. H. de Ligny L. Rostaing E. Thervet J. C. Szelag J.-P. Rérolle A. Rousseau G. Touchard P. Marquet 《American journal of transplantation》2007,7(11):2496-2503
Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In this 12-month study, 137 renal allograft recipients from 11 French centers receiving basiliximab, cyclosporine A, MMF and corticosteroids were randomized to receive either concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA AUC based on three-point sampling was used to individualize doses on posttransplant days 7 and 14 and months 1, 3 and 6. The primary endpoint was treatment failure (death, graft loss, acute rejection and MMF discontinuation). Data from 65 patients/group were analyzed. At month 12, the concentration-controlled group had fewer treatment failures (p = 0.03) and acute rejection episodes (p = 0.01) with no differences in adverse event frequency. The MMF dose was higher in the concentration-controlled group at day 14 (p < 0.0001), month 1 (p < 0.0001) and month 3 (p < 0.01), as were median AUCs on day 14 (33.7 vs. 27.1 mg*h/L; p = 0.0001) and at month 1 (45.0 vs. 30.9 mg*h/L; p < 0.0001). Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. 相似文献
5.
Surgery alone has long been the standard treatment for patients with operable non-small-cell lung cancer (NSCLC). However, despite complete resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suffering relapse and death from disease. Randomized trials conducted in the 1980s hinted at a survival benefit for postoperative cisplatin-based regimens, but they were underpowered. A meta-analysis published in 1995 found a nonsignificant 13% reduction in the risk of death associated with cisplatin-based chemotherapy, with an increase of survival of 5% at 5 years. This led to renewed interest in adjuvant chemotherapy in resected NSCLC. Thousands of patients have been included in a new generation of randomized trials in the last 10 years. Most of these recent studies have now been reported and several have demonstrated a clear survival advantage for patients treated with platin-based adjuvant therapy. These results also suggest a greater benefit with modern two-drug regimens. In view of the most recent data, postoperative platin-based chemotherapy can now be considered the standard of care for completely resected NSCLC patients with good performance status. 相似文献
6.
7.
Thierry A Folliguet Fabrice Vanhuyse Zanis Konstantinos Fran?ois Laborde 《European journal of cardio-thoracic surgery》2005,28(1):172-173
We report our initial experience with aortic valve replacement using robotic assistance. All procedures were performed with peripheral cardiopulmonary bypass, transthoracic aortic cross-clamp, and antegrade cold crystalloid cardioplegia. One or two ports and a 5-cm intercostal incision in the right chest were used for access. All patients had aortic valve replacement performed robotically. Between February and September 2004, five patients underwent robotic aortic valve replacement. The mean age was 59 years (range 35-82 years). There were no incisional conversions, death, stokes, or reoperations for bleeding. Overall mean study times were as follows: procedure, 231.2 min (range 180-315 min); cardiopulmonary bypass, 121.5 min (range 83-173 min), and cross-clamp, 98.2 min (range 67-140 min). One patient developed postoperative pneumonia. Aortic valve replacement can be successfully performed with the da Vinci robotic system. 相似文献
8.
Ladenstein Ruth; Pearce Rachel; Hartmann Olivier; Patte Catherine; Goldstone Tony; Philip Thierry 《Blood》1997,90(8):2921-2930
9.
Thierry Ponchon 《Acta endoscopica》2004,34(2):261-262
10.